Literature DB >> 14686492

Immunophenotypes and outcome of Philadelphia chromosome-positive and -negative Thai adult acute lymphoblastic leukemia.

Chirayu Udomsakdi-Auewarakul1, Orathai Promsuwicha, Chintana Tocharoentanaphol, Chanya Munhketvit, Kovit Pattanapanyasat, Surapol Issaragrisil.   

Abstract

Little evidence exists in Asian countries regarding the incidence, immunologic characteristics, and clinical outcomes of adult patients with Philadelphia chromosome-positive (Ph+) and -negative (Ph-) acute lymphoblastic leukemia (ALL). In this study, we prospectively studied 324 Thai adult acute leukemia patients, 79 (24%) of whom were identified as having ALL. Immunophenotyping was performed by 5-parameter flow cytometry, and karyotyping was conducted by standard banding methods. The Ph chromosome was detected in 18.5% of cases. The mean age of Ph+ ALL patients was 29 years (50% male), and that of Ph- ALL patients was 33 years (62% female). The Ph+ ALL patients had significantly higher white blood cell (WBC) counts (mean, 93 x 10(9)/L), with 67% having WBC counts higher than 50 x 10(9)/L. In contrast, most Ph- ALL patients had WBC counts lower than 50 x 10(9)/L (mean, 36 x 10(9)/L; P < .05). CD10 and CD34 were more highly expressed in the Ph+ ALL patients (mean expression, 83% and 87%, respectively) than in the Ph- ALL patients (45% and 57%; P < .005). The aberrant expression of myeloid antigens, including CD33 and CD13, was also significantly observed in the Ph+ ALL patients. The median survival time of Ph+ ALL patients was 8 months, compared with 22 months for the Ph- ALL patients. In conclusion, immunophenotyping results showed that Ph+ ALL in Thai adults arises from B-cells at an earlier stage of development. Extreme leukocytosis, a younger age, male sex, high expression levels of CD10 and CD34, aberrant myeloid antigens, and poorer rates of survival appeared to be associated with the Ph chromosome in Thai adult ALL cases. The incidence of the Ph chromosome among Thai adult ALL patients was not different from that found in Western countries.

Entities:  

Mesh:

Year:  2003        PMID: 14686492     DOI: 10.1007/BF02983559

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  40 in total

Review 1.  Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL).

Authors:  N Gökbuget; D Hoelzer; R Arnold; A Böhme; C R Bartram; M Freund; A Ganser; M Kneba; W Langer; T Lipp; W D Ludwig; G Maschmeyer; H Rieder; E Thiel; A Weiss; D Messerer
Journal:  Hematol Oncol Clin North Am       Date:  2000-12       Impact factor: 3.722

2.  Adult and childhood acute lymphoblastic leukemia: clinico-biological differences based on CD34 antigen expression.

Authors:  N Cascavilla; P Musto; G D'Arena; S Ladogana; R Matera; M Carotenuto
Journal:  Haematologica       Date:  1997 Jan-Feb       Impact factor: 9.941

3.  Immunophenotyping of leukemia.

Authors:  D Campana; F G Behm
Journal:  J Immunol Methods       Date:  2000-09-21       Impact factor: 2.303

Review 4.  Insights into the biologic and molecular abnormalities in adult acute lymphocytic leukemia.

Authors:  S Faderl; M Albitar
Journal:  Hematol Oncol Clin North Am       Date:  2000-12       Impact factor: 3.722

5.  Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.

Authors:  S Faderl; H M Kantarjian; D A Thomas; J Cortes; F Giles; S Pierce; M Albitar; Z Estrov
Journal:  Leuk Lymphoma       Date:  2000-01

6.  A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.

Authors:  R A Larson; R K Dodge; C P Burns; E J Lee; R M Stone; P Schulman; D Duggan; F R Davey; R E Sobol; S R Frankel
Journal:  Blood       Date:  1995-04-15       Impact factor: 22.113

7.  Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic findings outcome. A Collaborative Study of the Group Français de Cytogénétique Hématologique.

Authors: 
Journal:  Blood       Date:  1996-04-15       Impact factor: 22.113

8.  CD34 expression is associated with major adverse prognostic factors in adult acute lymphoblastic leukemia.

Authors:  X Thomas; E Archimbaud; C Charrin; J P Magaud; D Fiere
Journal:  Leukemia       Date:  1995-02       Impact factor: 11.528

9.  Myeloid markers in adult acute lymphocytic leukemia. Correlations with patient and disease characteristics and with prognosis.

Authors:  H A Preti; Y O Huh; S M O'Brien; M Andreeff; S T Pierce; M Keating; H M Kantarjian
Journal:  Cancer       Date:  1995-11-01       Impact factor: 6.860

10.  Long-term follow-up of adults with acute lymphoblastic leukemia in first remission treated with chemotherapy or bone marrow transplantation. The Acute Lymphoblastic Leukemia Working Committee.

Authors:  M J Zhang; D Hoelzer; M M Horowitz; R P Gale; D Messerer; J P Klein; H Löffler; K A Sobocinski; E Thiel; D J Weisdorf
Journal:  Ann Intern Med       Date:  1995-09-15       Impact factor: 25.391

View more
  2 in total

1.  Prognostic significance of immunophenotypic and karyotypic features of Philadelphia positive B-lymphoblastic leukemia in the era of tyrosine kinase inhibitors.

Authors:  Jesse Jaso; Deborah A Thomas; Krista Cunningham; Jeffrey L Jorgensen; Hagop M Kantarjian; L Jeffrey Medeiros; Sa A Wang
Journal:  Cancer       Date:  2011-03-01       Impact factor: 6.860

2.  Characterization of Immunophenotypic Aberrancies in Adult and Childhood Acute Lymphoblastic Leukemia: Lessons from Regional Variation.

Authors:  Mitra Sadat Rezaei; Najmeh Esfandiari; Sandra Refoua; Masoud Shamaei
Journal:  Iran J Pathol       Date:  2020
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.